SCHEMBL23488641

SCHEMBL23488641

CC1O[C@H](CNC(=O)c2ccc(OCc3ccccc3)cc2)[C@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC2 Q92769 2/20 0.49
NCOR2 Q9Y618 1/20 0.49
LMNA P02545 1/20 0.48
MAOB P27338 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488135 0.87 CA1 (0.61) HDAC3HDAC1HDAC2NCOR2LMNA
SCHEMBL23488504 0.87 ALDH1A1 (0.48) LMNAMAOBSMN1; SMN2MEN1KMT2A
SCHEMBL20234140 0.85 CA1 (0.50) CA1CA2CA9
SCHEMBL20234139 0.85 CA1 (0.50) CA1CA2CA9
SCHEMBL20234448 0.85 CA1 (0.50) CA1CA2CA9
SCHEMBL23488667 0.83 KDM4E (0.43) LMNASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL23488173 0.81 CHRNB2 (0.53) HDAC3HDAC1HDAC2NCOR2LMNA
SCHEMBL23488604 0.81 CHRNB2 (0.53) HDAC3HDAC1HDAC2NCOR2LMNA
SCHEMBL22490866 0.78 HDAC3 (0.52) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL23488692 0.75 MAOB (0.47) MAOBSMN1; SMN2RAB9ANR4A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 HDAC3 4081/4885HDAC1 3911/4885HDAC2 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.